<DOC>
	<DOCNO>NCT02504671</DOCNO>
	<brief_summary>This randomise , Phase IIb , dose-adaptive , multicentre , double-blind , parallel group , placebo-controlled study primary objective ass efficacy GSK3196165 , combination methotrexate ( MTX ) , subject active moderate severe rheumatoid arthritis ( RA ) despite treatment MTX . Approximately 210 subject randomise study , follow screen period four week . The total treatment period 52 week , 12-week follow-up period last dose ( Week 50 ) . Subjects randomise ( 1:1:1:1:1:1 ) placebo one five subcutaneous ( SC ) GSK3196165 dose , combination MTX ( weekly dose 15-25 milligram [ mg ] ) , previously receive least 12 week , stable tolerate dose route administration &gt; =4 week . Escape therapy provide specified timepoints protocol subject achieve adequate disease improvement .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety GSK3196165 Plus Methotrexate Subjects With Active Moderate-Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Age &gt; =18 year time signing informed consent . Meets ACR/EULAR 2010 RA Classification Criteria , disease duration &gt; =12 week . Swollen joint count &gt; =4 ( 66joint count ) tender joint count &gt; =4 ( 68joint count ) . DAS28 ( CRP ) &gt; =3.2 . CRP &gt; =5.0 milligram per litre ( mg/L ) screening . Must previously receive MTX ( 1525 mg weekly ) least 12 week screening , change route administration , stable tolerate dose &gt; =4 week prior Day 1 . A stable dose MTX &gt; =7.5 mg/week acceptable , MTX dose reduce reason document intolerance MTX , e.g . hepatic hematologic toxicity , per local requirement . Weight &gt; =45 kilogram ( kg ) . Male female subject eligible participate long meet agree abide contraceptive criterion . Diffusing capacity lung carbon monoxide ( DLCO ) &gt; =60 % predict ; force expiratory volume 1 second ( FEV1 ) &gt; =70 % predict No evidence active latent infection Mycobacterium tuberculosis ( TB ) . Pregnant lactating woman . History inflammatory rheumatological autoimmune disorder , Sj√∂gren 's syndrome secondary RA . History respiratory disease ( opinion investigator ) would compromise subject safety ability subject complete study ( e.g . significant interstitial lung disease , pulmonary fibrosis , chronic obstructive pulmonary disease ( COPD ) , moderatesevere asthma , bronchiectasis , previous pulmonary alveolar proteinosis [ PAP ] ) . Clinicallysignificant unstable ( opinion investigator ) persistent cough dyspnea unexplained . Significant unstable uncontrolled acute chronic disease , opinion investigator , could confound result study put subject undue risk . A history malignancy . Hereditary acquire immunodeficiency disorder , include immunoglobulin deficiency . Current/previous Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) 1 2 infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>DMARD-IR</keyword>
	<keyword>GSK3196165</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>